CoChat

In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model

Open access
Carreras, Alba, Pane, Luna Simona, Nitsch, Roberto, Madeyski-Bengtson, Katja, Porritt, Michelle, Akcakaya, Pinar, Taheri-Ghahfarokhi, Amir, Ericson, Elke, Bjursell, Mikael, Perez-Alcazar, Marta, Seeliger, Frank, Althage, Magnus, Knöll, Ralph, Hicks, Ryan, Mayr, Lorenz M., Perkins, Rosie, Lindén, Daniel, Borén, Jan, Bohlooly-Y, Mohammad, Maresca, Marcello · 2019 · BMC Biology
Cited by 91

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Plasma concentration of low-density lipoprotein (LDL) cholesterol is a well-established risk factor for cardiovascular disease. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates cholesterol homeostasis, has recently emerged as an approach to reduce cholesterol levels. The development of humanized animal models is an important step to validate and study human drug targets, and use of genome and base editing has been proposed as a mean to target disease alleles. RESULTS: To address the lack of validated models to test the safety and efficacy of techniques to target human PCSK9, we generated a liver-specific human PCSK9 knock-in mouse model (hPCSK9-KI). We showed that plasma concentrations of total cholesterol were higher in hPCSK9-KI than in wildtype mice and increased with age. Treatment with evolocumab, a monoclonal antibody that targets human PCSK9, reduced cholesterol levels in hPCSK9-KI but not in wildtype mice, showing that the hypercholesterolemic phenotype was driven by overexpression of human PCSK9. CRISPR-Cas9-mediated genome editing of human PCSK9 reduced plasma levels of human and not mouse PCSK9, and in parallel reduced plasma concentrations of total cholesterol; genome editing of mouse Pcsk9 did not reduce cholesterol levels. Base editing using a guide RNA that targeted human and mouse PCSK9 reduced plasma levels of human and mouse PCSK9 and total cholesterol. In our mouse model, base editing was more precise than genome editing, and no off-target editing nor chromosomal translocations were identified. CONCLUSIONS: Here, we describe a humanized mouse model with liver-specific expression of human PCSK9 and a human-like hypercholesterolemia phenotype, and demonstrate that this mouse can be used to evaluate antibody and gene editing-based (genome and base editing) therapies to modulate the expression of human PCSK9 and reduce cholesterol levels. We predict that this mouse model will be used in the future to understand the efficacy and safety of novel therapeutic approaches for hypercholesterolemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12915-018-0624-2

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 91

Metadata

Authors
Carreras, A., Pane, L. S., Nitsch, R., Madeyski-Bengtson, K., Porritt, M., Akcakaya, P., Taheri-Ghahfarokhi, A., Ericson, E., Bjursell, M., Perez-Alcazar, M., Seeliger, F., Althage, M., Knöll, R., Hicks, R., Mayr, L. M., Perkins, R., Lindén, D., Borén, J., Bohlooly-Y, M., & Maresca, M.
Venue
BMC Biology
Published
2019-01-15
Volume
17
Issue
1
Pages
4-4
ISSN
1741-7007 (ISSN-L)
OpenAlex
W2911627076
Cited by
91
References
20
FWCI
11.67
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. https://app.cochat.ai/papers/10.1186/s12915-018-0624-2
The paper
Carreras, A., Pane, L. S., Nitsch, R., Madeyski-Bengtson, K., Porritt, M., Akcakaya, P., Taheri-Ghahfarokhi, A., Ericson, E., Bjursell, M., Perez-Alcazar, M., Seeliger, F., Althage, M., Knöll, R., Hicks, R., Mayr, L. M., Perkins, R., Lindén, D., Borén, J., Bohlooly-Y, M., & Maresca, M. (2019). In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biology. https://doi.org/10.1186/s12915-018-0624-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.